Swiss pharma giant Novartis (NOVN: VX) has received an Accelerated Approval in the USA for its combination BRAF/MEK inhibitor therapy, for certain biomarker-defined tumors.
The nod makes the Tafinlar (dabrafenib) plus Mekinist (trametinib) treatment the first and only therapy of its kind available in a tumor-agnostic indication, for solid tumors carrying the BRAF V600E mutation.
This mutation is known to drive tumor growth in more than 20 different types of cancer, and the decision from the US Food and Drug Administration will bring a new treatment option for people with no alternatives.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze